The SAVI SCOUT Radar Localization System has been adopted by hospitals throughout the country. Brought to you by the same team behind the SAVI brachytherapy applicator, SCOUT
®
 is a FDA-cleared medical device used to provide tumor localization and real-time guidance during breast surgery. 

 
If you would like to be kept up to date on the latest information and updates regarding SCOUT, including details on clinical experience and product availability, you are invited
 to join the SCOUT Report® community.
 
In This Issue
Upcoming Events

 
Become a
Cent
er of Excellence in APBI!
 
Learn about becoming a Center of Excellence and find ways to grow your
APBI program by reaching out to referring physicians and women in the community.

Contact info@ciannamedical.com for more information.   
Follow-up Links

Past Issues

Cianna Medical

SAVI Sisters

November 2016 

New Standard of Care Offers Lower Toxicity, Shorter Treatment Times and Improved Cosmetic Outcomes for Women with Early Stage Breast Cancer

The
American Society for Radiation Oncology (ASTRO) announced an update to its Evidence-Based Consensus Statement for the use of Accelerated Partial Breast Irradiation (APBI) brachytherapy to include younger patients and those with low-risk ductal carcinoma in situ (DCIS).
  
ASTRO has updated its APBI Consensus Statement to reflect data from three large-scale randomized trials evaluating APBI vs. WBI. The data from these trials were sufficiently robust that committee voted unanimously to change the guidelines, expanding the group of patients for whom APBI brachytherapy is suitable, which now include patients ≥50 years of age (previous guidance included patients ≥60 years of age) Patients aged 40-49 years of age who meet all other elements of suitability were placed in the cautionary group.  This recent
Press Release was distributed by ASTRO.
Cianna Medical has partnered with Elekta to communicate the changes.   Both companies are committed to improving cancer care through developing innovative medical technologies and educating women about their options.   Key Opinion Leaders voiced their support of the ASTRO’s APBI guidelines consensus statement update.

 

Physician Perspectives
 
Frank A Vicini MD, FACR
 
“When the original ASTRO consensus statement was issued there was very little actual data on breast brachytherapy to deliver APBI. These guidelines have been updated based upon Phase III trial data, and results from more mature APBI trials. I think we should congratulate ASTRO for updating the guidelines, making them more applicable to the actual results obtained using APBI. I believe that 20-30% more patients will be suitable for APBI simply by reducing the age criteria and including patients with DCIS.”
Atif J. Khan MD, Director of Brachytherapy Services at the Rutgers Cancer Institute of New Jersey
“Evidence-based guidelines, such as those issued by ASTRO, have the potential to fundamentally alter
clinical practice. These important changes to ASTRO’s guidelines were based on a systematic review of 45 published clinical studies, resulting in a consensus decision to lower the recommended age group for APBI candidates from 60 to 50, significantly expanding the eligible patient population. Several recent clinical studies, including well-designed randomized trials directly comparing APBI to WBI, demonstrate that APBI brachytherapy offers potential advantages over WBI including a shorter course of treatment and decreased radiation while maintaining similarly low rates of cancer recurrence. We anticipate that ASTRO’s recommendations will drive significant changes in how clinicians approach early stage breast cancer treatment.”
Chirag Shah, MD, Cleveland Clinic, discusses
New Accelerated Partial Breast Irradiation Guidelines 

 

Julie A. Margenthaler
MD, FACS, professor, division of general surgery at Washington University School of Medicine, chair of American Society of Breast Surgeons communications committee.
“APBI brachytherapy is an attractive treatment option for many women with early stage breast cancer. It offers several advantages over WBI, while maintaining similar clinical outcomes, including the possibility of less radiation exposure to critical organs such as the heart, and improved cosmetic outcomes.  With the wide body of evidence supporting the safety and efficacy of APBI for women with early stage breast cancer and the guidelines update from ASTRO, we should soon see more widespread adoption of this clinically proven and convenient approach that targets only the tissue at risk and is kinder to patients.  Indeed, treating these women with whole breast radiation may represent overtreatment.”

A Patient Perspective
 
Rochelle Colon
 
“After being diagnosed with an
invasive ductal carcinoma in my left breast, I underwent six weeks of radiation therapy with many unpleasant side effects. I remained cancer free for 15 years and then it came back on my opposite breast. Fortunately, this time my cancer was treated with APBI brachytherapy in only five short days and I experienced none of the pain or discomfort that I had previously with a longer course of radiation.”